Men's health: modern diagnostics and new perspectives
In the month of November, the focus is on men's health. It is not just a healthy lifestyle that matters but also screening, early clarification of symptoms and awareness of individual health risks. With cancer in particular, a timely diagnosis and targeted therapy can be critical. At the Medical University of Graz, the Diagnostics and Research Institute of Human Genetics combines diagnostic expertise with research into the genetic and molecular basis of disease. Innovative approaches such as liquid biopsy are opening up new possibilities for increasingly personalized cancer treatment.
Detecting hereditary cancer risk
Most cancers are caused by genetic changes that arise over the course of a lifetime and are not inherited. In around five to ten percent of cases, however, there is an inherited predisposition to cancer. Indications may include familial clustering of certain types of cancer, an unusually early age of onset or several tumors in the same person. Genetic counseling can clarify whether genetic testing makes sense. "If a disease-causing change is detected, targeted screening can be offered to people who are affected and their family members if necessary. For people already suffering from cancer, genetic findings can also influence the choice of therapy," explains Jochen Geigl, head of the Med Uni Graz Diagnostic and Research Institute of Human Genetics.
Awareness of hereditary cancer risk is also important for men. Genetic mutations frequently associated with hereditary breast or ovarian cancer can also occur in men and be passed on to their children. Specific mutations, for example in the BRCA2 gene, may elevate the risk of prostate cancer as well.
Liquid biopsy: making use of molecular traces in the blood
Liquid biopsy is a specific research focus at Med Uni Graz. It can be used to test for cell-free DNA and circulating tumor DNA in a blood sample. This molecular evidence can provide information about genetic characteristics of a tumor and help to better assess disease progression as well as an individual's response to treatment. Particularly promising is testing for molecular residual disease (MRD), for example with regard to colon cancer. "After an operation, molecular genetic methods can be used to test for whether tumor-specific DNA is detectable in the blood. This can indicate a higher risk of recurrence and will enable treatment decisions to be made that are better suited to the individual situation," says Geigl.
The first clinical trials have yielded promising results. However, the best way to apply these results in the treatment decision-making process must be clarified before their broad use in routine clinical practice is possible. Liquid biopsy cannot be equated with a readily available blood test for early detection of all types of cancer. Its usefulness depends on the respective disease and the specific area of application.
Colon cancer and testicular cancer: screening and clarification count
Colon cancer frequently develops over the years out of initially benign changes in the mucous membrane, so-called polyps or adenomas. If they are detected early and removed during a colonoscopy, the development of cancer can be prevented. For people at an average risk, the recommended screening guidelines apply; for people with a hereditary predisposition to tumors, however, earlier and closer monitoring is necessary. Two examples are familial adenomatous polyposis (FAP), in which large numbers of intestinal polyps can form at a young age, and Lynch syndrome, which is also associated with an elevated risk of colon cancer. Genetic testing helps to identify family members at risk and introduce appropriate preventive measures in good time. General screening via colonoscopy is recommended for everyone starting at age 45.
Testicular cancer frequently affects younger men. Most cases occur sporadically. When several cases occur within a family—especially if a man's father or brother is affected—the risk is elevated. Changes or swelling in the testicles should be examined by a doctor promptly. The examples show how different screening and early diagnosis can be depending on the disease and individual risk, from established testing such as colonoscopy to targeted genetic clarification in families with higher cancer risk.
Research for more individualized cancer care
The work carried out at the Diagnostic and Research Institute of Human Genetics combines clarification of hereditary cancer risk with research into new molecular diagnostic methods. The goal is to use genetic information and molecular changes to better assess risks and increasingly individualize treatment decisions. "Collaboration with the clinical disciplines is essential. Genetic findings must be placed in a medical context and translated into appropriate prevention or treatment strategies," says Geigl. The Med Uni Graz Genetic Counseling Center offers genetic counseling and diagnostics to patients from Styria and at additional outpatient clinics in Carinthia and Burgenland.
November provides an occasion to raise awareness of men's health. The main message is to take advantage of recommended preventive screening, take complaints seriously and discuss familial cancer risk with a doctor. At the same time, research at Med Uni Graz is helping to improve diagnostics and lay the foundation for increasingly personalized cancer treatment.
Research into the latest methods for the early detection and treatment of cancer is carried out at the University Comprehensive Cancer Centre (Cancer Centre) in Graz. At this joint institution run by the University Hospital Graz and the Medical University of Graz, all university departments, institutes and divisions specialising in the diagnosis and treatment of cancer work closely together, thereby enabling the early detection and treatment of cancer.
Kontakt
Diagnostic and Research Institute of Human Genetics
Medical University of Graz